Parkside Financial Bank & Trust raised its stake in shares of Merck & Co., Inc. (NYSE:MRK) by 7.9% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 15,909 shares of the company’s stock after buying an additional 1,168 shares during the quarter. Parkside Financial Bank & Trust’s holdings in Merck & Co., Inc. were worth $1,339,000 at the end of the most recent reporting period.
A number of other large investors also recently made changes to their positions in MRK. Titan Capital Management LLC CA acquired a new stake in Merck & Co., Inc. during the 2nd quarter valued at $25,000. LFA Lugano Financial Advisors SA boosted its holdings in shares of Merck & Co., Inc. by 250.0% during the second quarter. LFA Lugano Financial Advisors SA now owns 315 shares of the company’s stock worth $26,000 after purchasing an additional 225 shares during the last quarter. JJJ Advisors Inc. acquired a new stake in shares of Merck & Co., Inc. during the second quarter worth $27,000. Cumberland Partners Ltd acquired a new stake in shares of Merck & Co., Inc. during the second quarter worth $40,000. Finally, Fusion Family Wealth LLC boosted its holdings in shares of Merck & Co., Inc. by 268.2% during the second quarter. Fusion Family Wealth LLC now owns 486 shares of the company’s stock worth $41,000 after purchasing an additional 354 shares during the last quarter. Hedge funds and other institutional investors own 74.95% of the company’s stock.
Shares of MRK traded up $0.71 during trading hours on Friday, hitting $83.59. The stock had a trading volume of 6,053,527 shares, compared to its average volume of 10,105,755. The company has a debt-to-equity ratio of 0.82, a quick ratio of 0.92 and a current ratio of 1.21. The firm has a market cap of $212.31 billion, a P/E ratio of 19.26, a P/E/G ratio of 1.80 and a beta of 0.54. The company’s fifty day simple moving average is $84.01 and its 200 day simple moving average is $82.77. Merck & Co., Inc. has a 12-month low of $70.89 and a 12-month high of $87.35.
Merck & Co., Inc. (NYSE:MRK) last issued its earnings results on Tuesday, October 29th. The company reported $1.51 earnings per share for the quarter, topping the consensus estimate of $1.24 by $0.27. The business had revenue of $12.40 billion for the quarter, compared to analyst estimates of $11.59 billion. Merck & Co., Inc. had a return on equity of 47.94% and a net margin of 20.26%. The business’s quarterly revenue was up 14.9% on a year-over-year basis. During the same period last year, the company posted $1.19 EPS. As a group, sell-side analysts predict that Merck & Co., Inc. will post 5.16 earnings per share for the current fiscal year.
Several research firms have recently issued reports on MRK. Bank of America began coverage on Merck & Co., Inc. in a report on Wednesday, October 16th. They set a “neutral” rating and a $90.00 price objective on the stock. Mizuho raised their price objective on Merck & Co., Inc. from $97.00 to $100.00 and gave the stock a “buy” rating in a report on Wednesday, October 30th. Societe Generale set a $105.00 price objective on Merck & Co., Inc. and gave the stock a “buy” rating in a report on Tuesday, September 3rd. Svb Leerink began coverage on Merck & Co., Inc. in a report on Friday, August 16th. They set an “outperform” rating and a $103.00 price objective on the stock. Finally, ValuEngine cut Merck & Co., Inc. from a “hold” rating to a “sell” rating in a report on Wednesday, October 2nd. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and thirteen have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average price target of $95.13.
About Merck & Co., Inc.
Merck & Co, Inc provides healthcare solutions worldwide. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, chronic hepatitis C virus, HIV-1 infection, intra-abdominal, fungal infection, insomnia, and inflammatory diseases.
Featured Story: What is range trading?
Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.